SCHEMBL7606100

SCHEMBL7606100

COC(=O)c1ccc(NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)c2ccsc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 3/20 0.53
MMP3 P08254 2/20 0.53
MMP7 P09237 1/20 0.53
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
ANPEP P15144 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
FPR2 P25090 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
STAT3 P40763 1/20 0.36
MMP2 P08253 1/20 0.35
FCER2 P06734 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606096 1.00 MMP1 (0.53) MMP1MMP3MMP7KDM4EMAPT
SCHEMBL7409388 0.92 MMP3 (0.43) MMP1MMP3MMP7KDM4EMAPT
SCHEMBL7409386 0.92 MMP3 (0.43) MMP1MMP3MMP7KDM4EMAPT
SCHEMBL7764954 0.89 MMP3 (0.56) MMP1MMP3MMP7L3MBTL1GAA
SCHEMBL7605447 0.89 MMP3 (0.56) MMP1MMP3MMP7L3MBTL1GAA
SCHEMBL7605453 0.89 MMP3 (0.56) MMP1MMP3MMP7L3MBTL1GAA
SCHEMBL7403919 0.85 MMP1 (0.52) MMP1MMP3MMP7KDM4EMAPT
SCHEMBL7403920 0.85 MMP1 (0.52) MMP1MMP3MMP7KDM4EMAPT
SCHEMBL7402055 0.77 MMP3 (0.42) MMP1MMP3MMP7MAPTATM
SCHEMBL7402056 0.77 MMP3 (0.42) MMP1MMP3MMP7MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6495699-B2 ANTIARTHRITIC AGENTS; OSTEOPOROSIS AGOURON PHARMACEUTICALS INC. 2002-12-17 US disclosed
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use BENDER STEVEN L (US) 2002-02-14 US disclosed
US-6306892-B1 ENZYME INHIBITORS HETEROCYCLIC AMIDES AGOURON PHARMACEUTICALS, INC. 2001-10-23 US disclosed
US-6174915-B1 FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY AGOURON PHARMACEUTICALS, INC. 2001-01-16 US disclosed
US-6008243-A AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES AGOURON PHARMACEUTICALS, INC. (US) 1999-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use MMP9, MMP2, MMP3 MMP1 8/4885MMP3 3/4885MMP7 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.